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Abstract 
The Development of Polysaccharide-based Nanoparticles for the Prevention of  
Foam Cell Formation during Atherosclerosis 
Kiran Ghandikota Murthy 
Yinghui Zhong, Supervisor, Ph.D 
 
Atherosclerosis is a complex, inflammatory disease that affects arteries and various cell 
types from the immune, circulatory, and metabolic systems. The progression of 
atherosclerosis can lead to coronary heart disease, one of the leading causes of death in 
developed nations. Some of the main factors that contribute to the progression of 
atherosclerosis are the oxidation of low-density lipoprotein (LDL), and the uptake of 
these oxidized products by macrophages within the intima of the blood vessels. The 
accumulation of oxidized LDL (oxLDL) within macrophages converts these cells into 
lipid-laden foam cells that contribute to the development of the atherosclerotic plaques. 
The death of accumulating foam cells within the atherosclerotic plaque leads to the 
formation of necrotic cores, which decrease the stability of the plaques, making them 
more thrombogenic. The resulting circulating thrombi can eventually cause myocardial 
infarction and death. Current methods of treatment for atherosclerosis, such as LDL 
apheresis and statin regimens, only makes the symptoms more manageable and do not 
treat the disease. Therefore, there is a need for a treatment of atherosclerosis that is able 
to target the mechanism which foam cells formation occurs, and inhibit this process. We 
propose a nanomedical approach for preventing the progression of atherosclerosis by 
inhibiting macrophage uptake of oxLDL. We have developed polysaccharide-based 
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nanoparticles that can bind to class A macrophage scavenger receptors to inhibit uptake 
of oxLDL. The physical properties of these nanoparticles were optimized in order to 
prolong blood circulation time and increase colloidal stability of the particles. The 
optimized nanoparticles effectively inhibited the uptake of oxLDL by macrophages in 
dose-dependent and time-dependent manners, indicating the therapeutic potential of these 
nanoparticles. 
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Chapter 1: Introduction to the Problem 
1.1. Atherosclerosis 
Atherosclerosis is a complex, inflammatory disease that affects large- and 
medium-sized arteries as well as various tissues and cells from the immune, circulatory, 
and metabolic systems [1, 2, 6, 10]. Atherosclerosis is a type of arteriosclerosis, in which 
the arterial walls thicken and harden, causing decreased elasticity of the blood vessels [1, 
6, 10]. Atherosclerosis involves the buildup of fatty plaques that results in the loss of 
integrity of the blood vessels [1, 2, 6, 10]. Physical rupture of this plaque can lead to 
myocardial infarction, which can result in death [2, 6]. Atherosclerosis and 
arteriosclerosis are one of the leading causes of cardiovascular diseases, which are the 
leading causes of death in developed nations [3, 4, 6]. According to the CDC, it is 
estimated that 2.6 million adults have been diagnosed with heart disease in the United 
States, which is about 11.3% of the adult population [5].  
The cause of atherosclerosis is not well understood. Several risk factors are 
known, such as obesity, sex, hypertension, familial hypercholesterolemia, diabetes, aging, 
and a sedentary lifestyle [6]. Many of these risk factors are controllable, such as the 
amount of physical activity one gets or habits such as smoking, whereas other risk factors, 
such as age or sex, are not modifiable. Inflammation due to accumulation of low-density 
lipoprotein (LDL) in the intima of the endothelial layer of the blood vessels is the 
defining characteristic of atherosclerosis, but the cause of this buildup is still unknown [2, 
6].  
 The amount of LDL in circulation is correlated with the progression of 
atherosclerosis [1, 2, 6, 9]. LDL (and other lipoproteins) is required to transport 
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cholesterol and other hydrophobic compounds throughout the body because they are not 
water-soluble, so a carrier is required to transport it throughout the body [6]. The main 
component of LDL that is required for formation and cholesterol transport is 
apolipoprotien B (apoB), and the accumulation of apoB in the atherosclerotic plaque is 
one of the factors important for the continued development of the plaque [6, 10]. 
Cholesterol is used for various activities in vivo, including signaling and cell membrane 
development and modification [6], which is why it is important for it to be transported 
throughout the body. Oxidation of LDL in the intima is also a popular hypothesis for the 
cause of atherosclerosis, but this has not been completely proven since administration of 
antioxidants to patients with atherosclerosis has not yielded significant results clinically 
[2, 7]. The buildup of atherosclerotic lesions is not harmful as long as it is contained 
within the intimal space [10]. However, once this plaque is destabilized due to breaching 
the endothelial layer and undergoing thrombogenesis, the risk for myocardial infarction 
greatly increases [10]. 
 
1.2. Cellular and Inflammatory Mechanisms of Atherosclerosis 
 The site of atherogenesis is the intima of the blood vessel. Many of the risk 
factors for atherosclerosis result in different aspects of atherosclerosis that affect the 
progression of the disease. Obesity contributes to hypercholesterolemia and other 
dyslipidemic conditions, and when the circulating lipids reach the hepatic portal 
circulation, very-low-density lipoprotein (VLDL) production increases, and this can 
lower the amount of circulating high-density lipoprotein (HDL) [2]. According to the 
CDC, having a higher amount of HDL is healthier than other lipoproteins because HDL 
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is able to transport more cholesterol per HDL molecule compared with smaller 
lipoproteins like LDL or VLDL [1, 2, 6–8, 10]. This does not lower the amount of 
circulating cholesterol, but rather groups more cholesterol into one macromolecule [6]. 
HDL is not considered to be an atherogenic lipoporotein or triglyceride, unlike LDL or 
VLDL, which is why it is considered healthier that the latter [16]. Obesity also 
contributes to the amount of inflammation due to the increased concentration of 
proinflammatory signals such as tumor necrosis factor (TNF) -α and interleukin (IL) -6 
[2]. An aspect of hypertension is increased production of angiotensin II, which acts as 
both a vasoconstrictor and an intimal inflammatory signal, and that induces the 
production of reactive oxidative species (ROS), such as C-reactive protein (CRP) [2, 8]. 
Diabetes also promotes the oxidative stress and the production of proinflammatory 
signals [2]. These ROS react with the accumulating LDL in the intima, producing 
oxidized LDL (oxLDL), an important macromolecule that is crucial for the progression 
of atherosclerosis [1, 2].  
 The main cells found in an atherosclerotic plaque include macrophages, dendritic 
cells, smooth muscle cells (SMCs), endothelial cells, and other leukocytes [1, 2, 6, 9, 10]. 
Macrophages are leukocytes that are a part of the immune system which are responsible 
for phagocytosis of foreign bodies such as microbes [6, 10]. They are differentiated from 
monocytes, which are short-lived but can be found circulating through the vasculature [6, 
10]. Macrophages are the key to the development and progression of atherosclerosis. 
 The atherosclerotic plaque begins to build up as LDL and lipids accumulate in the 
intima beneath the endothelial layer of the blood vessel [6].The accrual of LDL also 
increases the amount of apoB in the lesion, which activates the endothelial cells, inducing 
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upregulation of chemokines associated with monocyte attachment and recruitment to the 
lesion site [10].  The presence of ROS due to other risk factors for atherosclerosis leads to 
the oxidation of these lipids and LDL [9, 10]. Monocytes enter the subendothelial space 
and differentiate into macrophages due to the presence of oxLDL [9, 10]. Macrophages 
preferentially take up oxLDL, which leads to an increase in intracellular cholesteryl ester 
concentration [9, 10]. The buildup of cholesteryl esters leads to a downregulation of LDL 
receptors, and eventually converts the macrophage into a foam cell, the hallmark cell type 
of atherosclerosis [10]. Lipid-laden foam cells have little motility and are unable to 
degrade the excess LDL, possibly because oxLDL interferes with metabolic pathways 
that would normally break down of lipids and proteins [9]. oxLDL is also cytotoxic and 
immunogenic [9]. The differentiation of monocytes into macrophages produces ROS 
byproducts, which in turn produces more oxLDL to prohibit proper macrophage function 
[9]. The decrease in motility and increased cytoxicity of the lesion leads to the 
accumulation of foam cells within the lesion, which contributes to the development of the 
atherosclerotic plaque [9]. oxLDL also induces the increased expression of monocyte 
chemotactic protein-1 (MCP-1) and macrophage-colony secreting factor (M-CSF), two 
factors that induce further monocytic recruitment to the lesion and differentiation into 
macrophages once in the lesion [9]. Essentially, atherogenesis is a nonstop positive 
feedback loop that is dependent the recruitment of macrophages and converting 
macrophages into foam cells. 
 The activity of macrophages in the atherosclerotic lesion leads to smooth muscle 
inflammation and proliferation into the intima [6]. Activation of the SMCs promotes the 
formation of a fibrous cap composed of collagen around the atherosclerotic plaque [10]. 
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The buildup of cells in this inhibitory environment leads to the development of a necrotic 
core within the lesion, as well as the thinning of the fibrous cap due the decrease in the 
number of SMCs in the region [10]. SMCs also play a role in necrotic core formation 
because they secrete inflammatory and apoptotic factors TNFα and nitric oxide, 
respectively [10]. Certain factors secreted by macrophages, such as matrix 
metalloproteinases (MMPs), also aid in the degradation of the fibrous cap [10]. As the 
capsule thickness decreases, the stability of the plaque decreases, make it more 
susceptible to thrombosis [10]. This is also promoted by the secretion of prothrombic 
factors by the various cells in the atherosclerotic lesion [10]. 
 It can be concluded that the important factors for atherogenesis are macrophage 
recruitment and foam cell formation. This is because the accumulation of foam cells in 
the atherosclerotic plaque induces the positive feedback loop described earlier in which 
foam cell formation led to more recruitment, foam cell formation, inflammation and 
plaque growth. Therefore, therapies for atherosclerosis should target either of these 
mechanisms in order to effectively treat atherosclerosis.  
  
1.3. Current Clinical Treatments for Atherosclerosis 
 There are two main clinical treatments for atherosclerosis: LDL apheresis and 
statins. Unlike the strategies proposed earlier, these treatments focus on the reduction of 
circulating cholesterol and/or LDL in order to prevent the progression of atherosclerosis 
[6, 7, 11–15].  
LDL apheresis is a dialysis technique in which the blood of the patient is filtered 
in order to remove the excess LDL [11–13]. This done by passing the blood through 
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dextran sulfate (DS)-coated cellulose beads, and the LDL is removed from the blood 
because DS and apoB are oppositely charged [11–13]. This method is usually reserved 
for patients that have severe diet- or drug-resistant or familial hypercholesterolemia [12]. 
Another technique of LDL apheresis, known as heparin extracorporeal LDL precipitation 
(HELP), uses heparin to filter out precipitated LDL from circulation by first lowering the 
pH of the plasma which causes LDL to precipitate, and then filtering the precipitate from 
circulation with heparin [13]. The HELP system also led to a decrease in serum CRP 
concentration in patients, which would explain the reduction the rate of oxidation of LDL 
[13, 14], and it has also been shown to effectively treat hepatitis C [15]. High time 
consumption and high costs deter LDL apheresis from becoming more widely used [11, 
13]. It also does not cure the patient of the condition because the patient’s LDL 
cholesterol begins to increase after treatment, especially if the patient has familial 
hypercholesterolemia [11–14].  
The most extensively used clinical method currently used for the treatment of 
atherosclerosis is the prescription of statins [16–19]. Statins are drugs that inhibit hepatic 
cholesterol production by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG 
CoA) reductase, a rate-limiting enzyme involved in cholesterol production [16–19]. This 
leads to an upregulation of LDL receptors in the liver, causing hepatic uptake of the 
excess circulating LDL, as well as an increase in circulating HDL levels [16–19].  Statins 
also have antioxidant properties that prevent the formation of ROS which decreases the 
amount of circulating oxLDL, thus slowing the progression of atherosclerosis [18]. The 
drawback to statin treatment is that there are a myriad of side effects associated with a 
statin regimen, such as abnormal liver test results or possible liver damage, 
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gastrointestinal problems, and/or myopathy [16, 18, 19]. Rosuvastatin, one of the more 
potent statins prescribed to patients, was shown to reduce the atheroma volume and LDL 
cholesterol concentration after 24 months of treatment, but according to Nissen et al, this 
statin was the only one that is FDA-approved statin tested that can reduce atheroma 
volume because the other statins listed caused an increase in atheroma volume [16]. This 
is shown in Figure 1. This indicates that the statins may be effective in reducing the 
circulating LDL cholesterol levels, but atherogenesis is still occurring, and that the rate of 
atherogenesis may not differ in the presence of a statin because the change in atheroma 
volumes for two of the statins listed appear similar to placebo groups included in the 
figure. 
 
Figure 1: A plot of the change in median atheroma volume compared to mean LDL 
cholesterol concentration for three FDA-approved statins. These data were obtained from 
various clinical trials, This figure was obtained from [16]. 
 
1.4. Current Treatments Under Development 
 Due to the drawbacks of the current clinical approaches, other methods of treating 
atherosclerosis are currently being developed that can impede its progression. A popular 
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strategy has been to develop HDL mimetic drug delivery systems that target foam cell 
formation to induce cholesterol efflux and reverse the foam cell formation [20–25]. Other 
strategies include the use of antioxidants or anti-inflammatory agents to impede the 
progression of atherosclerosis [30, 31, 51]. HDL differs from LDL on the molecular scale 
because the primary apolipoprotein in HDL is apoA1, not apoB [6, 20, 21]. apoA1 has 
been shown to induce cholesterol and lipid efflux from cells, whereas apoB primarily 
transports cholesterol to cells [20, 21], which is why HDL is considered to be “good 
cholesterol” whereas LDL is considered to be “bad cholesterol” [1, 2, 6, 7, 20, 23]. 
Inducing cholesterol efflux is one way of targeting foam cells and causing foam cells to 
revert back into macrophages [21–24, 26].  
The complexity of the apoA1 lipoprotein (243 amino acids) increases the 
difficulty and cost of producing synthetic apoA1 that can be prescribed to patients, which 
is why there is compounds are being developed that act similarly to apoA1 and HDL [22–
24]. Decreasing the complexity of the protein is one approach being used, which would 
make it easier to produce the peptide in vitro and reduce the overall cost of 
manufacturing. This is the case with two apoA1 mimetic peptides: L4F and D4F, both of 
which have been tested in animals for efficacy [22, 24, 25]. L4F was shown to reverse 
atherosclerotic lesion development in mice and improve immune function in mice, and 
D4F was shown to significantly improve anti-inflammatory functions [22, 25]. L4F was 
also tested in humans, but the problem was that at concentrations that were successful in 
animal trials and at the human serum concentration of HDL, the apoA1 mimetic appeared 
to have no effect in vivo, and also increased the concentration of CRPs in circulation, 
which was also not observed in the animal trials [24]. 
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 Other strategies to mimic HDL function involve the use of nanomedical 
technology to target foam cell formation. Multifunctional micelles containing nuclear 
liver-X receptors (LXR) agonists were developed to target foam cells to block scavenger 
receptor-A (SR-A)-mediated oxLDL uptake, induce cholesterol efflux in order to revert 
foam cells back into macrophages [26, 27]. This approach resulted in a decreased 
inflammatory phenotypic expression in macrophages, thus showing that foam cells had 
been reverted into macrophages [1, 26, 28]. The drawbacks to this method include the 
decreased efficacy due to instability in vivo and the uncontrolled drug release [27, 29]. 
 The use of antioxidants and anti-inflammatory agents is another strategy 
employed to try and treat atherosclerosis. Current antioxidant treatments can slow the 
progression of atherogenesis, but do not improve clinical outcomes in patients [2]. 
Curcumin is an antioxidant polyphenol derivative that has had promising effects in terms 
of atherosclerotic and cancer treatments [30, 31]. It been shown to promote cholesterol 
efflux in vitro by upregulating the expression of cholesterol efflux-inducing SR-A and 
ATP-binding cassette type-A1 (ABCA1) [30]. Poor solubility in vivo has led to difficulty 
in administering this compound as a possible treatment for atherosclerosis [32]. Certain 
statins have been shown to have both antioxidant and anti-inflammatory properties, but 
these properties have not been enhanced in current drug development [18, 19, 33]. Rather 
than targeting foam cell formation, anti-inflammatory reagents target SMCs to reduce 
inflammation and recruitment of foam cells [33]. Some of the target molecules result in 
the production of ROS that end up aiding to the progression of atherosclerosis, so until 
the number of byproducts of those reactions decreases, this approach will not be feasible 
[33]. 
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1.5. Summary 
 Atherosclerosis, if left untreated, can lead to the development of cardiovascular 
disease and eventually result in death [1–6, 10]. Current treatments, such as statins and 
LDL apheresis, target the elevated LDL cholesterol levels, but this approach does not rid 
the patient of the disease [11–13, 16–19]. Other strategies are being developed, including 
HDL mimetics [20–22, 24, 25], multifunctional micelles [26, 27], and antioxidant and 
anti-inflammatory treatments [30, 33]. Each of these treatments has their own drawbacks, 
which is why there is a need for an alternative approach to treating atherosclerosis. 
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Chapter 2: Engineering Design and Experimental Overview 
2.1. Introduction 
As stated previously, the current treatments for atherosclerosis are not satisfactory 
due to unwanted side effects [13, 16], and cost and length of treatment [11–13]. A 
promising direction in current research is the development of drugs that can prevent foam 
cell formation through various methods, including HDL mimetics [20–22, 24, 25], 
multifunctional micelles [26, 27], and antioxidant and anti-inflammatory therapies [30, 
33]. Some of the drawbacks of these methods include lack of efficacy in vivo [24, 29, 32, 
33], as well as unwarranted side effects [33]. 
 
2.2. Problem Statement 
There is a need for the development of a nanomedical treatment that can prevent 
the formation of foam cells in order to impede the progression of atherosclerosis. This 
method must be able to prevent the intracellular accumulation of oxLDL in order to 
prevent the formation of foam cells in vitro without being cleared from circulation prior 
to effect without compromising stability or efficacy of the treatment. 
 
2.3. Specific Aims 
 The main deliverable will be a method to develop nanoparticles that consistently 
fit within the criteria and constraints listed. The parameters for the nanoparticles 
will be optimized using a multifactorial experimental design. 
 A major part of this deliverable will be the development of a computational model 
that will predict the size of the nanoparticles based on changes to the system. 
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 The nanoparticles developed should be able to inhibit oxLDL uptake in order to 
prevent foam cell formation, which will be tested in vitro. 
 
2.4. Criteria 
 The nanoparticles for this study should be composed of natural polymers. The 
polymers selected should be able to inhibit cholesterol uptake by macrophages in 
order to reduce intracellular cholesterol levels. 
 The size and charge of the nanoparticles must be optimized in order to prolong 
circulation time in vivo.  
 Nanoparticles must be able to inhibit the uptake of oxLDL in order to prevent the 
formation of lipid-laden foam cells.  
 
2.5. Constraints 
 The final size of the nanoparticles developed must be between 150 and 300nm in 
diameter in order to avoid renal and hepatic clearance, respectively [57, 58]. 
 The magnitude of the zeta potentials for the nanoparticles should be greater than 
25mV to show that the nanoparticles are stable and will not aggregate as easily 
[46, 47]. 
 The nanoparticles should have a negative surface charge in order to promote 
adhesion and uptake by macrophages [38]. 
 The polydispersity index (PDI) of the nanoparticles must be less than 0.3 in order 
to show that the size of the particles in solution can be considered uniform [46, 
47]. 
 The dose of nanoparticles administered should not induce cytotoxicity in vitro. 
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2.6. Decision Matrix and Selection of Polymers 
 Nanoparticles were selected in order to target foam cell formation due to reduced 
clearance rate compared to larger microparticles [34], the ability to be phagocytosed by 
cells [34], a high surface area-to-volume ratio that allows for better targeting of cells [34], 
and the potential to load advantageous drugs, peptides, or other biologically active 
molecules  into the nanoparticles in order to increase the efficacy and multifunctionality 
of the developed nanoparticles [26, 34 – 36]. 
Polysaccharides were selected as the components of the nanoparticles because of 
advantages that natural polymers have in this situation over synthetic polymers or 
liposomes. Synthetic polymers and liposomes can easily be modified and their physical 
properties can easily be controlled [37], but the main disadvantages are the 
hydrophobicity and the instability of these nanoparticles would lead to decreased efficacy 
in vivo [27, 29]. The atherosclerotic plaque is highly hydrophobic because of the 
increased lipid concentration [6], which would mean that there might be more 
localization of this type of particles in the plaque, but there would be accumulation of 
these particles anywhere where there is high lipid concentration, such as adipose tissue 
[37, 38]. There would also be decreased cell specificity because every cell has a 
hydrophobic cell membrane, and hydrophobic nanoparticles would be able to pass 
through this membrane of any cell [39]. Synthetic polymers can be modified to 
specifically target foam cells, but because of the reduced stability of synthetic 
nanoparticles, the amount of particles required and the amount of time for treatment 
would not be ideal [27, 29]. That was why natural polymers were selected as the main 
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components of these nanoparticles. Receptors for natural polymers can be found in nature 
[40], which means that the polymer does not have to be modified to target specific cells. 
Polysaccharides also have a natural cell adhesion trait which allows them to interact with 
cells [38]. Some polymers, such as dextran sulfate, are able to interact with receptors 
associated with cholesterol uptake, such as SR-A [40]. Because there is decreased 
specificity with hydrophobic nanoparticles and liposomes, hydrophilic natural polymers 
would be advantageous, given that they have receptors that are able to target foam cells. 
 In order for nanoparticles for form, two oppositely-charged polymers are required, 
interacting to form polyelectrolyte complexes (PECs) [42–44].The interaction between 
the polymers leads to steric changes within both polymers, resulting in individual particle 
formation [42–44]. The interaction of the oppositely charged polymers occurs to try to 
neutralize the difference in charge between the polymers, thus resulting in particle 
formation because it is entropically favorable [44]. The interaction of the charged 
polymers results in flocculation because the interaction of the oppositely-charged 
polymers results in neutral hydrophobic regions of the complexes and charged regions 
that are have not been neutralized [42, 44]. The neutralized hydrophobic regions contain 
more polymer chains than the charged regions, which results in more entanglement of the 
neutral regions [42, 44], which is why the inner portion of the PECs tend to neutral while 
the surface of the particles are charged [42, 44]. The mechanism suggested by Kabanov et 
al and Schatz et al can only occur when there is an imbalance in the ratio the 
concentration of polycation to polyanion, as well as an imbalance in the ratio of the 
charges [42, 44]. These steric charges can be seen with the Tyndall effect, in which 
solutions become more opaque as more particles form [43], as shown in Figure 2. 
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Figure 2: Images of the Tyndall effect in the solution of the nanoparticles developed. (a) 
A beaker of water is shown prior to the addition of any reagents to the solution. Shining a 
green laser through the solution does not result in scattering because there are not 
particles present to refract the line [43]. (b) Once the reagents have been added, particle 
formation occurs. When the laser is shone through the solution again, particles are able to 
refract the light, making the laser light visible. 
 
 
 In order to produce nanoparticles with a negative surface charge, the negatively-
charged component of the nanoparticles must be in excess. There are many possible 
candidates that were available for the negatively-charged component, such as dextran 
sulfate (DS), heparin sulfate (Hep), chondroitin sulfate (CS), and hyaluronic acid (HA). 
Of the polymers listed, only DS has been shown to inhibit cholesterol uptake via SR-A 
[40]. HA, Hep, and CS have also been shown to have affinities for LDL, though this 
varies based the location of the atheroma [45, 46]. However, only Hep was shown to 
induce cholesterol uptake via SR-A, not CS [46]. Hep and DS have both been used in 
current LDL apheresis technologies, indicating that they have an affinity for LDL [11–
15]. HA has not been shown to inhibit cholesterol uptake. HA is also easily degraded in 
the presence of ROS and by the enzyme hyaluronidase, and it is easily cleared in vivo 
because of its high solubility [47, 48]. All of the listed polymers have anti-thrombogenic 
properties [12, 14, 41, 49–51], whereas only DS, Hep, and CS also have anticoagulant 
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properties [14, 41, 49, 50]. Sulfonation of HA results in anticoagulation properties [50]. 
This information is summarized in Table 1. 
 
 
Table 1: Summarization of the pertinent properties of the possible polymers for the 
development of the nanoparticles. 
* indicates that the polymers are used clinically for LDL apheresis. 
 
  
 
 
Based on the information in Table 1, a decision matrix was used in order to 
determine which polymer was the most advantageous for the success of these 
nanoparticles, which is shown in Table 2. Scores were assigned on a scale from 0 to 3, in 
which 0 was the worst (property not sufficient) and 3 was the best (best properties 
available). Based on the presented information, DS was the best candidate for 
nanoparticle development because it has been shown to inhibit SR-A, thus preventing 
cholesterol uptake by the macrophage [40]. Hep and DS are both clinically used for LDL 
apheresis, which is why the score for LDL affinity was higher than the other anionic 
polymers [11–15]. Because HA is easily cleared and degraded in vivo, it was not suitable 
for prolonged circulation of the nanoparticles in vivo [48]. 
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Table 2: The decision matrix of the possible polymers. 
 
 
 
 
The second polymer selected to meet the criteria was the positively-charged 
polysaccharide chitosan. Nanoparticle formation between DS and chitosan has been 
studied extensively, which is why chitosan was selected for this thesis [42, 43]. The 
mechanism of this interaction will be explored in Chapter 3. 
 
2.7. Experimental Overview 
The main deliverables of this thesis is optimized nanoparticles which are able to 
prevent the formation of foam cells, and that have an average size between 150nm and 
300nm using a statistical model. The first part of the project was to optimize the 
parameters of the nanoparticles to ensure that the particle produced would being in the 
correct size range, and also ensure that the particles do not aggregate and become so large 
that they would be cleared in vivo. The model was developed by measuring how 
changing certain factors affected particle size. Once the nanoparticle size was optimized, 
the developed nanoparticles were used to treat macrophages to see how they would 
prevent oxLDL uptake. 
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2.8. Nanoparticle preparation 
Note: Stock concentrations of each reagent in the particle solution are italicized 
Solution 1 
20mL deionized (DI) water 
750µL Dextran Sulfate (Sigma-Aldrich): 4mg/mL (150µg/mL) 
 
Solution 2 
500µL DI water 
250µL Chitosan (Sigma-Aldrich): 4mg/mL dissolved in 0.6% acetic acid 
(60µg/mL) 
96µL CaCl2 solution: 10mg/mL (48µg/mL) 
 
1. Individual solutions of dextran sulfate (DS), chitosan, and CaCl2 were 
prepared at the italicized concentrations listed above. These solutions were 
prepared by dissolving the each polymer or salt in DI-water, except for 
chitosan, which was dissolved in 0.6% acetic acid solution. Solution 1 was 
prepared in a 100mL beaker, and Solution 2 was prepared in a 1.5mL 
Eppendorf microcentrifuge tube. 
2. Solution 2 was added to Solution 1 in a drop-wise manner. The particle 
solution was stirred on a stir plate between 9-10 krpm. 
3. After all of Solution 2 has been added, the particle solution was stirred for one 
minute, and then the stirring was stopped to avoid possible particle 
aggregation.  
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4. The initial size of the nanoparticles was measured prior to centrifugation. 1mL 
of the particle solution was added to a plastic cuvette, which was placed into 
the ZetaSizer® ZS100 NanoSeries. This machine was used to measure 
average diameter and/or the zeta potential of the particles in solution. 
5. Aliquots of the particle solution were made in 1.5mL microcentrifuge tubes, 
and the aliquots were centrifuged at 6krpm for 5-6 minutes 
6. The supernatant was removed from each aliquot, keeping on the pellet of 
nanoparticles. One pellet of nanoparticles was resuspended in 200µL of DI 
water, and this suspension was used to resuspend all of the pellets. This 
suspension was diluted to 1mL, and the size was measured again using the 
ZetaSizer. The nanoparticles were kept suspended until it was time to treat 
macrophages in vitro. 
7. When it was time for macrophage treatment, the nanoparticle solution was 
centrifuged again at 6krpm for 10 minutes. The supernatant was completely 
removed, and then 5µL DI water was used to resuspend the nanoparticles. 
This preparation amounted to 1.5x treatment of the macrophages in triplicate. 
 
2.9. Protocol for macrophage culture pre-treatment of nanoparticles 
1. All macrophage culture experiments were performed under sterile conditions. 
96-well plates were coated with 100µL 15ug/mL poly(d-lysine) (PDL) per 
well. The plates were incubated overnight at 37°C in sterile conditions 
overnight. Afterwards, each well was washed three times with sterile DI water, 
and then the plates were stored at 4°C until each experiment. 
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2. RAW 264.7 murine macrophages were thawed and stored at 37°C prior to the 
given experiment in a 5cm Petri dish until they were confluent. Cells were 
seeded at a density of 3 x 104 cell per cubic centimeter for each well (100µL 
per well) on a 96-well plate pre-coated with PDL. The remaining the cells 
were passaged to a new Petri dish at a ratio of 1:100 (v/v). If the macrophages 
were not used for experiments prior to confluency, the macrophages were 
passaged 1:100 (v/v) into a new 5cm Petri dish. After 28 passages, the cells 
were disposed and a new batch of cells was thawed. 
3. After seeding cells onto a 96-well plate, the cells were incubated overnight at 
37°C under sterile conditions. 
4. On the following day, cells were treated with nanoparticles at concentrations 
between 0.25x and 1.5x. This corresponds to a volume of nanoparticles added 
to each well in microliters in 100uL media (DMEM (10-017-CV) + 10% FBS 
+ P/S) per well. Everything was performed in triplicate under sterile 
conditions. The treated cells were incubated at 37°C under sterile conditions 
for the given incubation period, between one hour and 24 hours. 
5. After incubation, the particles were washed away using sterile phosphate-
buffered saline (PBS), and then the cells were treated with media treated with 
20 µg/mL oxLDL. Cells were the incubated overnight at 37°C under sterile 
conditions. 
6. On the following day, the number of cells was quantified using an Alamar 
Blue assay. Following this assay, cells were fixed using 4% paraformaldehyde. 
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2.10. Oil Red O Staining 
1. Oil Red O was dissolved in 100% isopropanol at 40mg/mL. This solution was 
shaken, and then the undissolved precipitate was removed using filter paper. 
2. The filtered solution was diluted with DI water by adding two parts of Di 
water for every three parts isopropanol. The diluted solution was filtered again 
using a syringe filter. 
3. Fixed cells were washed three times with PBS, and then 60% isopropanol 
(diluted in DI water) was added to each well for five minutes. Afterwards, the 
isopropanol solution was removed and 90µL Oil Red O solution was added 
for to each well for 12 minutes. 
4. After incubation, each well was washed twice with 60% isopropanol for 5-10 
seconds twice, and then with PBS twice. Images were obtained using 
brightfield microscopy. After brightfield microscopy, the PBS was replaced 
with 60% isopropanol for ten minutes, and then the absorbance was measured 
with the TECAN ® Infinite 200 with a wavelength of 520nm. Absorbances 
were normalized to the negative control. 
 
2.11. Measurement of DS Entrapment 
1. The nanoparticles were prepared using the method described above. The 
discarded supernatant was saved for measuring the loading of each 
polysaccharide in the nanoparticles. The loading of DS was measured using 
Toluidine Blue O (TB), while the loading of chitosan was measured using 
Orange II. 
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2. The supernatant was centrifuged at 10krpm for 10 minutes, and the 
supernatant was saved again. The pellet obtained from this centrifugation was 
discarded. 
3. For the TB assay, the supernatant was diluted 1:10 with DI water, and then 
200µL diluted supernatant was added to 100µL TB solution. The reaction 
mixture was vortexed for a minute, and then incubated at room temperature 
for 10 minutes. 
4. After incubation, the reaction mixture was centrifuged at 10krpm for 10 
minutes, and then 100µL was placed into a well on a 96-well plate. The 
absorbance was measured at a wavelength of 584nm. 
5. A standard curve was produced by serial dilution of DS solutions starting at 
100µg/mL. Steps 1 – 4 of this protocol was repeated for the standard solutions 
to obtain the standard curve in order to obtain the concentration of DS in the 
supernatant, which can be used to calculate the amount of DS that had been 
loaded into the nanoparticles. 
 
2.12. Measurement of Chitosan Entrapment 
1. The nanoparticles were prepared using the method described above. The 
discarded supernatant was saved for measuring the loading of each 
polysaccharide in the nanoparticles. The loading of chitosan was measured 
using Orange II. 
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2. The supernatant was centrifuged at 10krpm for 10 minutes, and the 
supernatant was saved again. The pellet obtained from this centrifugation was 
discarded. 
3. For the Orange II assay, the supernatant was diluted 1:100 with 0.5M NaCl 
solution (pH 7.0), and then 900µL diluted supernatant was added to 100µL 
Orange II solution. The reaction mixture was vortexed for a minute, and then 
incubated at room temperature for 15 minutes. 
4. After incubation, the reaction mixture was centrifuged at 10krpm for 30 
minutes, and then 100µL was placed into a well on a 96-well plate. The 
absorbance was measured at a wavelength of 484nm. 
5. A standard curve was produced by serial dilution of chitosan solutions starting 
at 80µg/mL. Steps 1 – 4 of this protocol was repeated for the standard 
solutions to obtain the standard curve in order to obtain the concentration of 
chitosan in the supernatant, which can be used to calculate the amount of 
chitosan that had been loaded into the nanoparticles. 
 
2.13. Summary 
 In order to develop a more potent treatment for atherosclerosis, nanoparticles will 
be developed composed of DS and chitosan that are able to inhibit SR-A function, thus 
preventing macrophages from uptaking oxLDL, and ultimately preventing foam cell 
formation. The properties of these nanoparticles will be optimized using a multifactorial 
design in order to produce particles within the given size range and surface charge that 
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will prolong their circulation time in vivo. These particles will also be tested in vitro in 
order to determine their efficacy in preventing oxLDL uptake. 
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Chapter 3: Nanoparticle Characterization and Development 
3.1. Introduction to Nanoparticle Formation 
 In order to treat atherosclerosis, foam cell formation was targeted in order to 
prevent the progression of the disease because the accumulation of foam cells had been 
shown to be detrimental to the stability of the atherosclerotic plaque [9, 10]. Current 
treatment methods, such as statin regimens or LDL apheresis, only prevent the buildup of 
circulating LDL, which mediates the symptoms of atherosclerosis, but does not treat the 
disease [11–13, 16], which is why a different target was needed. 
 As stated earlier, DS has been shown to inhibit cholesterol uptake in animal 
studies by blocking class-A scavenger receptors (SR-A) [40]. DS has also been shown to 
possess both anti-thrombogenic and anticoagulant properties, making it ideal for treating 
atherosclerosis [41]. However, the DS solution has not been tested in clinical trials in 
humans, suggesting that it may not be as effective by itself. The nanoparticles produced 
by DS and chitosan interactions have been studied extensively [42, 43], which was why 
chitosan was selected as the second component for these nanoparticles. Figure 3a and 3b 
shows the molecular structures of both DS and chitosan.  
Once the polymers were selected, the next criteria included the size and stability 
of the nanoparticles. Because the essential effects on foam cells were caused by DS, the 
polyanion had to be on the surface of the nanoparticle while chitosan had to be in the 
center of the particle. Kabanov et al described that for more efficient PEC formation, one 
polymer had to be in excess, resulting in both a charge and molar imbalance [44]. Schatz 
et al described the results of different combinations of DS and chitosan at different 
molecular weights, as shown in Figure 3c. The combinations shown are of high 
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molecular weight (HMW) DS or chitosan with low molecular weight (LMW) chitosan or 
DS such that the surface charge of the nanoparticles were either positive or negative [42]. 
The positively-charged particles were those with excess chitosan, whereas the negatively-
charged particles were those with DS in excess [42]. Since DS is required to be on the 
surface, the overall surface charge of the nanoparticles should be negative; therefore, 
excess DS was necessary for the experiment. According to Schatz et al, combining 
excess LMW DS with HMW chitosan resulted in unstable PEC formation because the 
amino groups on the chitosan chain made the polymer stiffer, thus unable to reconfigure 
into a stable particle [42]. Also, DS is more flexible and charged than chitosan, so using 
excess LMW DS with HMW chitosan would result in charge neutrality, causing 
decreased stability and aggregation to occur [42–44]. The stiffer polymer chains would 
also result in larger particles after particle flocculation, which is why HMW chitosan was 
not selected [42]. According to Schatz et al, using LMW DS would yield no stable 
products [42]; therefore, the remaining option was combining HMW DS and LMW 
chitosan, which is why these two polymers were selected for this experiment. 
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Figure 3: Molecular structures of the polymers used for the nanoparticle preparation, as 
well as the particle formation mechanisms for various conditions. (a) Dextran sulfate is 
negative-charged due to the presence of the sulfate groups. (b) Chitosan is the positively-
charged polymer selected for these nanoparticles because it has been shown to form 
PECs with DS. The positive charge is due to the presence of the amino groups present on 
the molecule. (c) HMW DS was used for this experiment in conjunction with LMW 
chitosan because this was the conformation that would lead to DS being on the surface of 
the nanoparticles. Four situations are illustrated: (c1) and (c3) show the interaction 
between LMW DS and HMW chitosan, whereas (c2) and (c4) show the interaction 
between HMW DS and LMW chitosan. (a) and (b) were obtained from Delair, 2011 [43], 
and (c) was obtained from Schatz et al, 2004 [42]. 
 
 
 
3.2. The Effects of Metal Cations on Particle Size and Surface Charge 
Because both DS and chitosan have high binding affinity for metal ions [52–55], 
the effects of magnesium (Mg2+) and calcium (Ca2+) metal ions on particle size and 
stability were tested. Chitosan has been shown to chelate divalent metal ions [52, 53], and 
in circulation it has been shown to bind to cholesterol in the presence of metal ions [54]. 
DS, in the presence of Ca2+, increases the production of HDL in vivo [55], thus increasing 
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the potential multifunctionality of the nanoparticles in vivo. Because of these traits, metal 
ions were tested in conjunction of the two polysaccharides. 
For this experiment, the ratio of DS to chitosan (DS:CH) was selected to be 3:1. 
Three conditions were tested: no metal ion added, 48 µg/mL CaCl2 added, or 48 µg/mL 
MgCl2 added to chitosan prior to being added to the particle solution. Nanoparticles were 
centrifuged and resuspended twice for this experiment. The long-term stability of the 
particles was determined by measuring the nanoparticle diameter and PDI every day for 
two weeks using the ZetaSizer NanoSeries ZS90 (referred to simply as ZetaSizer). The 
particles were kept in 1mL solutions at 4°C for this experiment, and were only removed 
from that temperature to measure the diameter of the nanoparticles. The results on the 
size are shown in Figure 4.  
Figure 4a shows that the size did not change over time with or without the 
presence of metal ions. The metal ion that was added, however, changed the size of the 
particles drastically. The addition of Ca2+ caused the particles to decrease in size, whereas 
the addition of Mg2+ caused the particles to increase in size. The data for each day were 
compared using one-way ANOVA, and the p-values obtained were 0.9759 for Ca2+, 
0.4378 for Mg2+, and for the nonionic condition, it was 0.1011. These p-values indicate 
that there was no significant change in size over time for any condition.  
Figure 4b shows the distribution of the polydispersity indices (PDIs) for each day 
of measurement when correlated with the size of the nanoparticles. It can be seen that the 
addition of metal ions has an effect on the PDI and the size, as there is no overlap 
between the clusters that form. The PDI increases with the addition of Mg2+, but does not 
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appear to change with the addition of Ca2+. The only difference between the Ca2+ and the 
nonionic conditions was the decrease in size, which was also shown in Figure 4a.  
 
 
 
Figure 4: The effects of metal cations on particle size and PDI. Three conditions were 
tested with and without a metal cation present in the particle solution. Inclusion of Mg2+ 
resulted in the largest particles, whereas inclusion of Ca2+ resulted in the smallest 
particles. (a) The change in particle size over time when the particles are stored at 4°C. 
(b) The scattering of the PDI and sizes over three weeks shown together to determine 
how little change has occurred in each condition. 
 
 The change in size was apparent due to the addition of metal cations to the 
particle solution, which was why the change in zeta potential was measured to see if the 
metal ions affected the stability of the nanoparticles. When particles and colloids are in 
solutions with other ions, the ions that have the opposite charge of the surface will be 
electrostatically attracted to the surface of the particle initially, producing the Stern layer 
[53, 54]. The Stern layer forms due to electrostatic attraction to try to neutralize the 
particles due to entropy, but if the surface charge of the particle is high enough, the Stern 
potential will not be enough to neutralize the surface charge [54]. The potential at the 
boundary between the Stern layer and the diffuse layer of ions in solution is the zeta 
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potential, which is also the difference in potential between the Stern layer and the surface 
charge [53,54]. If the magnitude of the surface charge is not high enough, the Stern layer 
could neutralize the particle, decreasing the colloidal stability, thus increasing the chance 
that there is aggregation of multiple particles [42, 44, 54]. Since the zeta potential is the 
difference between the Stern potential and the surface charge, the greater the magnitude 
of the zeta potential, the more stable the particle is because it indicates that electrostatic 
repulsion is occurring between particles, thus prohibiting aggregation [53,54]. This is 
summarized in Figure 5.  
 
 
 
Figure 5: The definition of zeta potential. The first layer that forms around a colloid is the 
Stern layer, composed of ions with the opposite charge of the surface. The zeta potential 
is the difference between the surface potential and the Stern potential, corresponding to 
the stability of the nanoparticle because it indicates the likelihood that the particles would 
aggregate due to electrostatic attraction. Images obtained from Zeta-Meter manual [54]. 
 
 
Using the ZetaSizer, the zeta potential of the different nanoparticle solutions was 
measured. The nanoparticles were prepared the same way as previously mentioned. The 
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size and zeta potential were measured weekly for three weeks. Figure 6 shows the 
differences in zeta potential and the nanoparticle diameters as a result of the addition of 
the different metal cations.  
From Figure 6a, the difference in size as a result of the addition of different metal cations 
can be seen. The p-values from one-way ANOVA are also shown comparing the 
differences in size based on the groups listed. There is a significant difference between all 
of the groups in this experiment (p<0.05), as well as a significant difference in size 
between the addition of Ca2+ or Mg2+. This supports the results in Figure 5, indicating 
that the type of metal does have a significant effect on the particle size.  
 
 
 
 
Figure 6: The differences in zeta potential as a result of different metal cations. (a) The 
change in nanoparticle diameter was measured weekly, corresponding to the change in 
zeta potential in (b). The two tables displayed contain the p-values of the one-way 
ANOVA used to compare the listed conditions. There is a significant difference in size 
based on the presence of a metal ion. The metal ions have the same valency, which is 
why there is a similar reduction in zeta potential, so it can be assumed that the zeta 
potential and the valency do not play a role in the determining the size of the nanoparticle. 
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The zeta potentials that corresponded to the given size measurements are shown in Figure 
6b. All of the zeta potentials obtained are negative, supporting the idea that DS is on the 
surface on the nanoparticles since DS is in excess and HMW DS was used for developing 
these nanoparticles [42]. The addition of either Ca2+ or Mg2+ resulted in zeta potentials 
with lower magnitudes than the nonionic conditions. This could be caused because of the 
presence of excess metal ions in solution that are able to form a larger Stern layer around 
each nanoparticle, thus lowering the zeta potentials of the respective nanoparticles. The 
difference between the presence of Ca2+ or Mg2+ was not significantly different, and this 
could be due to the fact that Ca2+ and Mg2+ have the same valencies and similar 
electronegativities; therefore, the electrostatic interaction between the negatively-charged 
nanoparticles and positively-charged metal ions might be similar [59]. Even though the 
sizes are significantly changed when the metal ions, the zeta potentials are not 
significantly different from one another, indicating that there is a different parameter 
outside of the scope of this design that is causing the change in size of the nanoparticles. 
Because Ca2+ was able to reduce the size of the nanoparticles, it was kept in the 
nanoparticle formulation over the formulations with Mg2+ or without metal ions. 
 
3.3. The Effects of Centrifugation on Particle Size 
 An aspect of the DS-chitosan nanoparticles that has not mentioned in the literature 
was that the average nanoparticle diameter changes due to centrifugation. The sizes 
reported in the literature are similar to those obtained prior to centrifugation, but these 
values change afterward [42, 43]. Sizes of the obtained particles were measured prior to 
centrifugation, if it occurred, but not after. In the static solution, electrostatic repulsion is 
33 
 
enough to maintain the colloidal shape of the nanoparticles, but centrifugal forces are 
able to overcome the electrostatic repulsion between particles, inducing aggregation. As 
centrifugation speed increased, the change in size also increased, which also led to 
changes in PDI. This is shown in Figure 7, where the centrifugation speed of the 
nanoparticles was increased during the two centrifugation phases of the particle 
production method.  
 
 
Figure 7: The effects of centrifugation on particle size (a), PDI (b) and the ZetaSizer 
count rate (c). There is an increase in both particle size and count rate as centrifugation 
speed increased, a decrease in PDI. The count rate is comparable to the concentration of 
the nanoparticles in solution, which means that the yield of large, possibly uniform 
particles increases with centrifugation speed. 
 
 
DS(Ca) nanoparticles were prepared for each speed tested. The size of the 
nanoparticles was measured using the ZetaSizer, prior to centrifugation. The particle 
solutions were centrifuged at the appropriate speeds, and once the particles were 
resuspended, the sizes were measured again. The particle solution was centrifuged again 
at the same speed as they were for the first centrifugation, and the particles were 
resuspended again, followed by size measurement. This was repeated in triplicate for 
each centrifugation speed. One-way ANOVA was used to analyze as well as how these 
properties changed due to centrifugation, as well as the effects of the centrifugation speed. 
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These results were supported by the Tukey-Kramer test to determine where there was the 
most effect. 
Figure 7a shows how the size of the nanoparticles changes as centrifugation speed 
increases. In some cases, the diameter of the nanoparticles more than doubles in size due 
to the aggregation associated with centrifugation. Between the initial particles, there was 
no statistical difference prior to centrifugation (p>0.05). After the first centrifugation, 
there were significant differences between the sizes as centrifugation speed increased 
(p<0.05), but the significant difference decreased during the second centrifugation since 
the p-value obtained from ANOVA for this situation was greater than the one obtained 
during the first centrifugation, but it still indicated significant differences between the 
particle sizes. 
Figure 7b shows how the PDI of the solution is changing, which corresponds to 
the distribution of particle sizes in solution. A low PDI indicates that the various particles 
sizes are close to uniformity, while a high PDI indicates that the particles sizes in solution 
are too polydisperse, which means that the average diameter measured by the ZetaSizer 
may not be accurate [49]. The PDI increased more as the centrifugation speed was 
reduced, which could mean that some of the particles were affected by the centrifugal 
forces, causing some aggregation. The decrease in PDI as centrifugation speed increased 
could be indicative of more uniform aggregation occurring during centrifugation as the 
nanoparticles become larger. The PDI values are not significantly different initially and 
for the first centrifugation, but after the second centrifugation, the difference in PDI 
values became significant because of the difference in PDI values due to centrifugation at 
2000rpm, and 5000rpm and 6000rpm, based on the results from the Tukey-Kramer test. 
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Figure 7c shows the change in the count rate as centrifugation speed increases. The count 
rate can be correlated to the concentration of particles in solution, though not very 
accurately [49]. An increase in the count rate can be a result of increasing concentration 
of nanoparticles in solution, but it might not by the same margin of increase as the count 
rate. That is why the count rate is only shown to compare the yield of particles since it 
drastically changes as centrifugation speed increased. The lower speeds resulted in a 
lower yield of particles for that condition, and the yield increases as centrifugation speed 
increased. The count rate also varied greatly between triplicates, making it the 
measurements less substantial. This was why the count rate was excluded from the 
constraints of the nanoparticle development. Significant differences were observed after 
the first and second centrifugation events. For speeds greater than 6000rpm, the results 
were not significant.  
From these observations, the centrifugation speed selected for the remainder of 
the experiments was 6000rpm. Centrifugation speeds less than this led to a decrease in 
yield of nanoparticles (which was observed and correlated with the count rate of the 
ZetaSizer) even though the original sizes of the nanoparticles were preserved. The 
average PDI of the particles that resulted from the centrifugation at 6000rpm was also the 
lowest one obtained, meaning that this condition produced the particles with the most 
uniform size. That is why this centrifugation speed was selected for this experiment. 
 
3.4. Multifactorial Analysis of Nanoparticle Components 
 Once the metal cation and the centrifugation speed were finalized, the remaining 
conditions for the development of the nanoparticles were the DS:CH ratio, the 
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concentration of Ca2+ added, the total volume of the solution, and the concentration of 
chitosan (and the equivalent DS concentration) . These conditions were analyzed using a 
multifactorial experimental design to determine the effects of these conditions on particle 
size. 
 Nanoparticles were prepared by varying the four conditions above. There were 
three levels for each condition except for the concentration of chitosan, for which there 
were two levels. The levels and parameters for this experiment are shown in Figure 8. 
Combinations of the different levels were used to produce nanoparticles to observe the 
combined effects of the given parameters on nanoparticle size and zeta potential, 
resulting in 54 possible groupings. This experiment was performed in triplicate, and the 
diameter of the nanoparticles was measured using the ZetaSizer. 
 
 
Figure 8: An overview of the multifactorial experiment in order to optimize the 
parameters of the nanoparticles. Four main parameters with 2 – 3 levels each were 
modified in order to determine which conditions would yield the nanoparticles that fit the 
size and stability requirements. The four main parameters were the total volume of the 
particle solution, the final concentration of chitosan in the particle solution, the 
volumetric ratio of DS to chitosan, and the concentration of CaCl2 added to the particle 
solution. The levels selected for this experiment were selected based on previous 
unpublished research from our lab. 
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 In order to analyze the data from the multifactorial analysis, a factorial ANOVA 
could be used [57]. However, one of the criteria of using this this tool was that the data 
were normally distributed, and the data collected were not normally distributed (see 
Appendix) based on the results the Kolmogorov-Smirnov test [57]. Therefore, 
nonparametric tests were required to analyze these data [57]. Also, since there were four 
independent variables being measured and one dependent variable, a four-way 
nonparametric ANOVA would have been required to completely analyze these data [57]. 
However, this type of analysis does not exist, which is why the analysis of the different 
parameters had to be altered [57]. 
 In order to simplify this analysis, the different variables were combined into a 
ratio of the sum of the cationic components (Ca2+and chitosan) to the sum of the anionic 
components (DS). First, the volumes that were added were converted to final 
concentrations using the stock concentration, and the total volume and the volume of for 
each component using Equations 1: 
[component]      =
          
      
[component]      
, where Vcomponent is the volume of the given component (DS, chitosan, or Ca
2+), and Vtotal 
is the total volume for the given trial. Once the concentrations were obtained, the cationic 
components were summed and a ratio was calculated between the sum of the cationic 
components and the anionic component, shown in Equation 2: 
charge	ratio =
[Ca ] + [CH]
[DS]
 
This calculation was performed for each combination of the different levels in Figure 8. 
This reduced the analysis so that the Kruskal-Wallis nonparametric one-way ANOVA 
could be used to interpret the data, which can be seen in Figure 9a [57]. The Kruskal-
(2) 
(1) 
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Wallis ANOVA was used on the data after the conditions that produced particles that 
were greater than 300nm in diameter after centrifugation were removed, since those 
conditions would not meet the criteria of the given nanoparticles. This can be seen in 
Figure 9b. A p-value of 0.017 was obtained, indicating the groups are significantly 
different from one another. Using a Tukey-Kramer post-hoc test, no significant difference 
was seen between the different charge ratios, except for the differences between three 
groups, shown in Figure 9c.  
The condition that produced the smallest particles out of the remaining charge 
ratios was selected as the optimized condition, which produced nanoparticles that initially 
had an average diameter of 151nm, and an average diameter of 209nm after the first 
centrifugation. These sizes are This condition had a DS:CH  volumetric ratio of 3:1, a 
final concentration of 5 µg/mL chitosan, and 48 µg/mL CaCl2, and a total volume of 
20mL. This condition is the one listed in the protocol in Chapter 2, as well as the 
conditions that were used for the experiments prior to this one. 
 
Figure 9: The results of the multifactorial analysis of nanoparticle components. (a) The 
charge ratios were developed using the parameters that were altered in the multifactorial 
experiment. The charge ratios that were greater than 1 were removed because of the 
increased variance in the data. (b) The parameters in red were removed because the sizes 
after centrifugation were too large (above 300nm +5% error in diameter), leaving only 
the parameters in blue to be analyzed with the Kruskal-Wallis ANOVA. This resulted in 
a p-value of 0.017, indicating that the charge ratios resulted in in significantly different 
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sizes, so the optimized parameters selected would be the unique compared to other 
conditions that could have been tested. (b) This plot shows the results of the Tukey-
Kramer post-hoc after the Kruskal-Wallis analysis. The only parameter charge ratio that 
showed any significant difference from the other groups was 0.1633, which contained the 
conditions of choice. All of the other conditions had overlapping scores with other 
possible conditions, indicating that the significance was caused by the means showed 
here. Images produced using MATLAB. 
 
3.5. Modeling the Effects of Each Parameter on Nanoparticle Size 
The data collected for the multifactorial analysis were also used to develop a 
computational model that could predict the size of nanoparticles based on input 
conditions. The data from the multifactorial analysis were used to develop this model in 
MATLAB because MATLAB was developed as a data-processing program that could 
use and analyze inputted data, making it superior to other programming languages. This 
model estimated nanoparticle size based on linear interpolation between known 
conditions (see Appendix for MATLAB script). The use of linear interpolation was the 
main assumption of this model. The four conditions that were altered for this model were 
the volume of chitosan added, the ratio of DS:CH, the total volume of the solution, and 
the volume of CaCl2 added. The concentrations of the solutions were assumed to be the 
same as the ones used for the previous experiment. Figure 10a shows the results of the 
computational modeling compared to the actual data collected. Figure 10b depicts the 
remaining particle sizes when conditions that produced particles with a diameter greater 
than 300nm were excluded. Figure 10c shows the error of the computational model. The 
error is not correlated with size, and it ranges from no error (0%) to nearly 600%. The 
average error for this model is about 40%, which means that the validity of the model is 
questionable. 
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Figure 10: Computational modeling of the collected data to predict the size of the 
nanoparticles. (a) The results of the modeling shown in blue with the actual data shown in 
red. (b) The predicted data that were greater than 300nm in diameter were removed to 
compare the predicted data and the actual data. (c) The error between the predicted sizes 
and the actual sizes were calculated, showing there was no correlation in the error of the 
prediction and the actual data. 
  
3.6. Loading of Chitosan and DS into Nanoparticles 
 The loading of each polymer was tested by measuring the amount of each 
polymer remaining in the supernatant after centrifugation to collect the nanoparticles. 
Toluidine Blue O was used for measuring the remaining DS concentration, and Orange II 
was used to measure the remaining chitosan concentration. After reaction with the excess 
polymers, the absorbance of the reaction mixture was measured using the TECAN 
Infinite ® M1000 Pro, and the measured absorbances were correlated to a concentration 
with a measured standard curve (see Appendix).  
 The entrapment efficiency of a polymer is defined in Equation 3: 
Etrapment	efficiency	(%) =
       	    	  	             
       	       	    
× 100% 
This was calculated for each polymer, and the results are shown in Figure 11. The 
entrapment of both polymers was above 95%, suggesting that most of the polymers added 
to solution reacted to form nanoparticles.  
(3) 
41 
 
 
Figure 11: The entrapment efficiency of each polymer in the nanoparticles, calculated by 
measuring the absorbance of the unreacted polymers remaining in the supernatant after 
centrifugation. 
 
3.7. Summary 
 Nanoparticles were optimized in order to develop a new treatment for 
atherosclerosis. These particles were composed of DS, a negatively-charged 
polysaccharide known to inhibit cholesterol uptake and bind to positively-charged 
chitosan, a non-cytotoxic, positively-charged polymer that could bind with DS in order to 
induce nanoparticle formation via electrostatic attraction [40–43]. The size and zeta 
potential of the nanoparticles were optimized to be within the range of 150nm to 300nm 
in diameter, and more negative than -25mV, respectively. This was done to increase 
stability of the nanoparticles and prolong circulation time in vivo [38, 44, 58].  
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Chapter 4: Nanoparticle Pre-Treatment of Macrophages 
4.1. Introduction to Cellular Cholesterol Uptake Mechanisms 
 As demonstrated previously, foam cell formation plays a critical role in 
atherosclerotic plaque development. One of the factors that induce foam cell formation is 
the uncontrolled accumulation of cholesterol within the cell through certain influx 
mechanisms [62]. The uptake of oxLDL occurs through scavenger receptors, specifically 
SR-A and CD36 [62].Once the protocol for nanoparticle development had been produced 
and optimized, the efficacy of the nanoparticles was investigated. Nanoparticles were 
tested for dose-dependent and time-dependent activity prior to oxLDL treatment onto 
murine macrophages in vitro. Oil Red O (ORO) staining was another method used to 
visualize the remaining intracelluluar cholesteryl ester.  
 
4.2. Dose-dependent treatment of DS(Ca) Nanoparticles 
 The first test of efficacy was to show that pre-treatment of the nanoparticles could 
reduce intracellular cholesterol concentration. RAW264.7 murine macrophages were 
cultured on PDL-coated 96-well plates prior, and were treated with 0.25x, 0.5x, or 1x of 
DS(Ca) for 24 hours. The concentration represents volumes (in microliters) of 
nanoparticles added to the 100µL murine macrophage media prior when the media was 
refreshed for the experiment. Afterwards, the nanoparticles were washed away and the 
cells were treated 20ug/mL oxLDL for 24 hours. Two controls were included in this 
experiment: a positive control that was treated with oxLDL for both days, and a negative 
control in which the macrophages were untreated. The cells were fixed with 4% 
paraformaldehyde after 24 hours, followed by ORO staining. Brightfield images of the 
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stained cells were obtained at 20x magnification. Figure 12 shows the images of the dose-
dependent treatment of DS(Ca) nanoparticles after ORO staining. The TECAN® Infinite 
200 (TECAN) was used to measure the luminescence was measured after ORO staining 
(λ = 520nm).  
The results of the ORO staining are shown in Figure 12. ORO binds to cholesteryl 
esters and tryglycerides, both of which accumulate intracellularly as macrophages 
become foam cells [61]. This specificity is the reason why ORO can be used to 
differentiate macrophages from foam cells [61]. The images that appeared to be the most 
red were the positive control (Fig. 12e) and the 0.25x condition (Fig. 12a), which shows 
that this dose of nanoparticles was not high enough to prevent foam cell formation. The 
higher doses of nanoparticles (0.5x and 1x) both appear similar to the negative control, 
indicating that the accumulation of internalized cholesterol was irrelevant. Absorbance 
values were obtained and normalized to the negative control. The absorbances were 
analyzed with one-way ANOVA, and the results obtained reflect what was observed in 
the stained images. All of the treated cells were significantly different from the positive 
control (p<0.05), and only the 1x DS(Ca) dose was not significantly different from the 
negative control (p>0.05). A dose response was observed in Figure 12f, indicating the 
effects of the nanoparticles could potentially be therapeutic. 
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Figure 12: The ORO-stained images of the dose-dependent pre-treatment. The images 
show the remaining intracellular cholesteryl ester after subsequent nanoparticle and 
oxLDL treatment. (a) The 0.25x DS(Ca) treatment group. (b) The 0.5 DS(Ca) treatment 
group. (c) The 1x DS(Ca) treatment group. (d) The negative control, which were cells 
that were not treated with either oxLDL or nanoparticles. (e) The positive control, which 
was only treated with only oxLDL. (f) The luminescent quantification of ORO after 
imaging. There is a decrease in ORO luminescence as the nanoparticle dose increases, 
indicating efficacy of the nanoparticles. All of the nanoparticle treatment groups had a 
significant difference from the positive control (PC), and each treatment group was 
significantly different from the negative control except for the 1x DS(Ca) condition. * 
indicates that the group is significantly different from PC, and # indicates that the group 
is different from NC (p < 0.05). ** indicates that the groups are significantly different 
from one another (p < 0.05). Image magnification was 20x. Scale bar = 200µm. 
 
4.3. Time-dependent treatment of DS(Ca) Nanoparticles 
 The next experiment performed was to show the time-dependence of the DS(Ca) 
nanoparticle treatment. The highest dose was used from the previous experiment (1x) 
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because it was the most consistent through repeated experiments. The consistency of this 
condition allowed for modulation of the time parameter to show that the change in the 
amount of time for treatment was the only variable in the experiment. 
 RAW 264.7 murine macrophages were cultured on PDL-coated plated prior to 
treatment. The three time spans were 24 hours, 5 hours, and 1 hour. 1x DS(Ca) 
nanoparticles were treated and removed after the given time span, and then 20µg/mL 
oxLDL was administered to the pre-treated cells for 24 hours. The cells were fixed using 
4% paraformaldehyde, followed by ORO staining and imaging, followed by absorbance 
measurements. 
The ORO staining results are shown in Figure 13. The images for the treatment 
groups appear to have little to no differences since the dose selected had already been 
shown to work (see Figures 13a–c). The ORO stained images here show little to no 
staining compared to the positive control, indicating that most of the cells in each 
condition were macrophages, not foam cells. This shows that treatment by the DS(Ca) 
nanoparticles begin working as soon as the particles come in contact with the cells, 
though it is unclear whether or not the particles are taken up by the cells are not. 
 Quantification of the ORO staining reveal an decrease in the amount of ORO 
staining as the treatment period increases, which is shown if Figure 13f. The treatment 
groups were all significantly different from the positive control, according to one-way 
ANOVA, and the only treatment group that was significantly different from the negative 
control was the 1-hour treatment group. In that case, there might not have been enough 
time for the nanoparticles to settle onto the cells at the bottom of the well, which is why 
the complete effect of the nanoparticles were not seen after one hour. Unlike in the 
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previous section, the time-dependence can be seen, but it is not as significant as the dose 
dependence seen in Figures 12f. 
 
 
 
 
Figure 13: The ORO-stained images of the time-dependent pre-treatment. The images 
show the remaining intracellular cholesteryl ester after subsequent nanoparticle and 
oxLDL treatment. (a) The 24-hour treatment group. (b) The 5-hour treatment group. (c) 
The 1-hour treatment group. (d) The negative control, which were cells that were not 
treated with either oxLDL or nanoparticles. (e) The positive control, which was only 
treated with only oxLDL. (f) The luminescent quantification of ORO after imaging. The 
luminescence values were normalized to the negative control. There is an increase in 
ORO luminescence as the nanoparticle dose increases, indicating efficacy of the 
nanoparticles. All of the nanoparticle treatment groups had a significant difference from 
the positive control (PC), and only the 1-hour treatment was significantly different from 
the negative control (NC). * indicates that the group is significantly different from PC, 
and # indicates that the group is different from NC (p < 0.05). Image magnification was 
20x. Scale bar = 200µm. 
 
47 
 
 
4.4. Summary 
 Once the nanoparticle characteristics had been optimized to prolong circulation 
time in vivo, the efficacy of the nanoparticles had to be tested in order to show that the 
proposed treatment would be able to prevent foam cell formation. This was tested in vitro 
by tested both dose-dependence and time-dependence properties of the nanoparticles. 
Figures 12 and 13 show the efficacy of the nanoparticles are by showing that with 
increasing doses, there is a decrease in intracellular cholesterol content. This suggests that 
these nanoparticles are able to induce prevent oxLDL uptake. The longer the treatment 
time, the more efficacious the nanoparticles are, suggesting that the prolonged interaction 
of the nanoparticles with the cells is able to have lasting effects on the macrophages even 
after the particles are washed away. These lasting changes could be changes in gene 
expression, meaning that the particles would not need to be present for the effects to be 
seen (which is why the effects are observed even after the particles are washed away); or 
the changes could be based on nanoparticle uptake into the cell, which would mean that 
the particles would have to be present in order for these effects to be long-lasting. 
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Chapter 5: Discussion and Conclusion 
5.1. Summary of the Problem 
Coronary heart disease is the leading cause of death in developed nations, and it is 
one of the potential results of untreated atherosclerosis [1–6, 10]. Atherosclerotic plaques 
develop within the intima of mid- and large-sized arteries, and the progression of the 
disease decreases the stability of the plaque [1, 2, 6, 10]. The decrease in stability 
increases the thrombogenicity of the plaque, and the production of circulating thrombi 
from the unstable plaques could lead to myocardial infarction and possibly death, if left 
untreated [2, 6].  
Even though the cause of atherosclerosis is unknown, there are certain traits of the 
disease that affect the progression of the disease. High circulating cholesterol 
concentrations are usually associated with atherogenesis, but this is not causative [1, 2, 6, 
7, 9]. Conditions – for example, hypertension, obesity, or diabetes – that increase the 
production of circulating proinflammatory signals, such as TNF-α and IL-6, can lead to 
the increased production of reactive oxidative species (ROS) [1, 2, 6, 8, 16]. The 
accumulation of LDL within the intima of the blood vessels increases the likelihood that 
it is oxidized, forming oxLDL, which is crucial to the progression of the disease [1, 2, 8, 
9, 10]. 
The accumulation of LDL and lipids in the blood vessel intima increases apoB 
concentration in the intima, which activate endothelial cells and upregulates the 
production of chemokines that induce monocytic attachment and recruitment to the lesion 
site [6, 10]. The presence of oxLDL in the lesion causes the differentiation of monocytes 
into macrophages as monocytes penetrate the endothelial layer of the blood vessel [10]. 
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Preferential uptake of oxLDL by macrophages increases intracellular cholesteryl ester 
concentration, which downregulates LDL receptors on the cell surface and potentially 
interferes with cellular pathways to break down lipids and proteins, thus converting them 
into foam cells [9, 10]. Foam cells contribute to the atherosclerotic plaque because they 
have decrease mobility compared to macrophages, and the cytotoxicity of the lesion is 
only increasing as ROS byproducts, LDL, and oxLDL lead to increased monocytic 
recruitment, macrophage differentiation, and foam cell formation [9, 10]. The decreased 
foam cell motility and increased cytotoxicty contributes to the development of a necrotic 
core in the atherosclerotic plaque, which decreases the stability of the plaque and makes 
it more thrombogenic [10]. 
Current treatments of atherosclerosis include statins regimens and LDL apheresis 
[6, 7, 11–19]. Both treatments target the high circulating LDL concentration in order to 
combat atherosclerotic development [11–13, 16–19].The drawbacks of statin regimens 
are the myriad  of associated side effects, and the fact that atherogenesis is not reversed 
by this method [16, 18, 19]. The drawbacks to LDL apheresis is the amount of time 
required for the procedure, the high cost of the treatment, and the fact that it is reserved 
for patients with familial hypercholesterolemia [11–14]. Other strategies implemented 
include the development of HDL and apoA1 mimetics [22–25], drug delivery of LXR 
agonists [26–28], or the development of antioxidants or anti-inflammatory drugs [30, 31, 
58]. However, these approaches have not yielded sufficient results in vivo or in human 
trials (as is the case for the apoA1 mimetics) because of decreased stability, efficacy, or 
uncontrolled drug release in vivo [2, 24, 27, 29, 32, 33]. 
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Because of the role that foam cell formation plays in atherosclerotic development, 
these cells were selected as a more suitable target for developing a new approach for 
treating atherosclerosis. By targeting foam cell formation rather than circulating LDL 
concentration, the positive feedback of foam cell formation and recruitment of new cells 
would be impeded because of the decrease in necrotic core development, which would 
decrease the risk of thrombus formation, hence reducing the risk of myocardial 
infarctions. By inhibiting foam cell formation, the progression of the disease could be 
halted, thus allowing for atherosclerosis to be treated completely. Therefore, we proposed 
the development of a nanomedical approach to prevent foam cell formation in order to 
disrupt progression of the disease.  
 
5.2. Nanoparticle Characterization 
The proposed design utilized nanoparticles composed of two oppositely-charged 
natural polysaccharides: dextran sulfate (DS), and chitosan. DS was selected because it 
has been shown to prevent cholesterol uptake by blocking SR-A, a receptor know for 
causing the influx of cholesterol [40]. Electrostatic attraction between DS and chitosan 
and polymer chain entanglement causes PEC formation, which can be seen in Figure 3 
[42–44]. Constraints on the nanoparticles included size (must be between 150nm and 
300nm in order to avoid hepatic and renal clearance [68, 69], and the nanoparticles also 
needed a zeta potential with a magnitude greater than 25mV in order to show prolonged 
stability [57, 58]. The PDI of the produced nanoparticles had to be less than 0.3 in order 
to be considered uniform [58]. 
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A problem that initially arose was the change in size due to centrifugation. 
Originally, it was not reported in centrifugation would drastically increase the size of the 
nanoparticles. The centrifugal forces that occurred were larger than the effect of 
electrostatic repulsion of similar surface charges, causing the particles aggregate and 
increasing the average diameter of the nanoparticles (see Figure 7). The change in size 
varied with different properties of the nanoparticles, ranging from changes in 
centrifugation speed to changes in total volume or other changes in the multifactorial 
experiment (Data not shown). This changed the experimental design by requiring the 
initial particle size to be decreased enough that after centrifugation twice, the 
nanoparticles would still be in required range to prolong circulation in vivo. 
Figure 4 and 6 demonstrate that introducing Ca2+ into the nanoparticle system 
further decreased the size of the nanoparticles. While Ca2+ led to a decrease in particle 
size, Mg2+ introduction led to an increase in particle size, even though the change in zeta 
potential were very similar for either ion (see Figure 6). Therefore, the metal ions were 
interacting with the polymers through a different interaction other than electrostatic, since 
the size changes were significantly different based on the type of ion added, but the zeta 
potential changes were not significantly different, as seen in Figure 6. The reason for this 
difference in mechanism was outside of the scope of this thesis. 
 
5.3. Statistical and Computational Modelling 
 In order to optimize the conditions of the nanoparticle preparation, a 
multifactorial analysis was performed in order to compare the effects of added chitosan 
volume, added CaCl2 volume, the DS:CH ratio, and the total particle solution volume, as 
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shown in Figure 8. The data obtained were not normally distributed within their 
parameters (see Appendix), requiring a nonparametric analysis of variance to determine 
which points were statistically significant from the others. Because of the number of 
independent variables included in the analysis, a four-way nonparametric ANOVA would 
have been required to properly analyze these data. However, since this type of analysis 
does not exist, assumptions had to be made in order to simplify the data. Charge ratios 
were calculated for each condition using Equation 2, and then data were removed if the 
size after one centrifugation event produced particles that were outside of the size 
constraints, and then the data were analyzed using the Kruskal-Wallis nonparametric 
ANOVA. The results, shown in Figure 9, indicated that the group that contained the 
smallest produced nanoparticles was also the only group that was significantly different 
from multiple other charge ratios, based on the Tukey-Kramer post hoc test. 
 The data that were collected for the multifactorial analysis were also used for the 
development of a computational model that could predict the size of nanoparticles based 
on input conditions. The only requirement was that they had to be within the ranges of all 
of the data collected. This computational model interpolated the sizes based on the 
conditions that were the most similar to the input conditions in order of importance based 
on the volume of chitosan added, the DS:CH ratio, the total volume of the solution, and 
the CaCl2 volume added. Once the similar conditions were selected, and then applied a 
weighted mean to the corresponding sizes in order to calculate the predicted size. The 
effectiveness of this model is shown in Figure 10, where the largest error of this mode 
was slightly less than 600%, but the average error was about 40%, based on estimation of 
known values. This error was most likely due to the presence of the weighted means of 
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all nearby conditions. The predicted sizes were affected by the assumptions that the data 
changed linearly (which was linear interpolation was used) and because of the weighted 
mean of the similar conditions. Therefore, in order to improve this computational model, 
more data would have to be collected based on other conditions tested to allow for the 
linear interpolation to be more accurate. 
 
5.4. Pre-treatment of Nanoparticles 
 Once the parameters of the nanoparticles were optimized, the efficacy of the 
nanoparticles was shown in vitro through dose-dependent and time-dependent pre-
treatment of the RAW 264.7 murine macrophages by the developed nanoparticles. The 
macrophages were treated with nanoparticles for a given time period, and then the 
particles were removed and the cells were then treated with oxLDL in order to see if 
foam cell formation was induced or not. Cells were stained with ORO in order to 
determine the effects of the nanoparticles on intracellular accumulation of cholesterol. 
Quantification of the ORO absorbance supported the results of the images collected. 
Dose-dependence was shown in Figures 12, whereas time-dependence was shown in 
Figure 13. Significant decreases in ORO luminescence was observed between all of the 
treatment groups and the positive control, which contained the only foam cells. ORO 
luminescence increases with increasing intracellular cholesteryl ester concentration, 
which is how oxLDL is stored once it has been taken up by the macrophages [65]. 
 The dose-dependent and time-dependent activities suggest that the nanoparticles 
induce a change in the cellular mechanism of  oxLDL uptake. Since the nanoparticles 
were washed away after treatment, the effects on the cells occurred must have occurred in 
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the absence of the particles, unless some of the particles were taken up by the cells, and 
therefore not washed away. Another possibility is that not all of the nanoparticles were 
washed away. After pre-treatment, streaks of a membrane could be seen on the surface of 
the cells, so the cells were washed until this membrane was gone. Figure 14 shows an 
image of this membrane. If all of the particles were not washed away prior to oxLDL 
treatment, then another situation would need to be taken into account where both the 
particles and oxLDL are present in solution, and how this affects foam cell formation. 
 
 
Figure 14: An image of the membrane that forms above the layer of cells prior to washing 
the particles during pre-treatment. 
 
 5.5. Future Work 
 Improvements can be made to the design of the nanoparticles in order to increase 
the multifunctionality of the nanoparticles. Drugs can be loaded into the nanoparticles, 
which is why Ca2+ was originally included in the nanoparticle design [56]. Anti-
inflammatory drugs, such as minocycline, or antioxidants such as curcumin, could 
potentially be loaded into the nanoparticles in order to increase the functionality of the 
nanoparticles, possibly to allow the nanoparticles to be used for broader applications, 
such as cancer treatment if curcumin were loaded into the nanoparticles [30, 31, 56]. The 
use of more polymers is also a possibility. Heparin has been shown to have an affinity for 
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LDL as seen in LDL apheresis that utilize the HELP system [13]. Heparin has been 
shown to have anticoagulant activity, which could be potentially useful in terms of 
multifunctionality of the nanoparticles if it can be loaded into the nanoparticles [13]. 
However, the efficacy of the nanoparticles must be maintained if either of these methods 
are carried out. 
The efficacy of the nanoparticles has been shown in both a time-dependent and 
dose-dependent manner. Both nanoparticle and oxLDL treatment simultaneously has 
already been shown to be efficacious by our lab (unpublished data), as well as when 
oxLDL is applied first to the macrophages, followed by nanoparticle treatment 
(unpublished data). Therefore, the next step would be testing the effects of these 
nanoparticles in vivo in an animal model. Testing in an animal model will show how 
effective these particles can be in a dynamic environment rather than in a static 
environment in vivo. The effects of different components in blood and serum will also be 
tested to see if they affect the efficacy of the nanoparticles.  
 In order to improve the computational model developed, more data would need to 
be collected. More conditions would need to be tested in order to increase the accuracy of 
the linear interpolations of the model, and once enough data has been collect, a new 
model could be developed in order to extrapolate the size of the nanoparticles based on 
known data. Right now, there were only 54 different conditions tested in triplicate, but 
this was not enough to draw meaningful conclusions from extrapolation, which is why 
more data are required. 
 
56 
 
5.6. Conclusions 
 Because of the drawbacks of current treatments for atherosclerosis, a new method 
of treatment was needed in order to prevent foam cell formation to prevent the 
progression of atherosclerosis. nanoparticles were developed that would be able to 
prevent macrophages from becoming foam cells, which was shown in vitro. The 
properties of these nanoparticles were optimized to prolong the circulation time in vivo, 
but this has not been proven yet. The next step of this research would be to test the 
efficacy of these nanoparticles in an animal model to show that the nanoparticles are not 
cleared from circulation as quickly because of the optimization of the properties of the 
nanoparticles. 
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Appendix 
A.1.MATLAB code for the multifactorial analysis  
%% Multifactorial analysis (Take 3) 
% So there is no such thing as a four-way non-parametric ANOVA, so I 
need 
% to simplify the conditions that I am considering. 
  
close all; clc,clear 
load('multifactorial_data_v3.mat'); 
  
%% Simplifications 
% Convert everything to concentrations so that Vol_total does not 
have to 
% be taken into account, reducing the number of parameters to three. 
The 
% concentrations are in ug/mL. 
CH=4.*CHVol./totalVol; % unique [CH] = {25, 50, 100, 200} ug/mL 
DS=4*CHVol./totalVol.*DSCHrat; % unique [DS] = {25, 50, 75, 100, 150, 
200, 300, 600, 1200} ug/mL 
Ca=10.*CaVol./totalVol; % unique [Ca] = {0, 24, 48, 96, 192} ug/mL 
  
% Simplify everything based on charge. A ratio of positively-to-
negatively 
% charged elements was produced by summing the CH and Ca 
concentrations, 
% and dividing them by the DS concentrations. This reduced the 
system to 
% only one variable, and only requires a one-way nonparametric 
ANOVA! 
  
chargeRatio=(CH+Ca)./DS; % unique(chargeRatio)={0.1667 0.2467 0.3267 
0.3333 0.4867 0.4933 0.6533 0.9733 1.0000 1.4800 1.9600 2.9200} 
plot(chargeRatio,Sizes_initial,'.'); 
xlabel('Charge ratio');ylabel('Size'); 
[p1,~,stats1]=kruskalwallis(Sizes_initial, chargeRatio); % 
p1=1.425e-20 
compare=multcompare(stats1); 
  
% That last three charge ratios have a much higher variance than the 
rest 
% of the data, so the analysis was run again without those data 
points. 
modifiedChargeRatio=chargeRatio(chargeRatio<1.48); 
modifiedSizes=Sizes_initial(chargeRatio<1.48); 
figure(4); 
plot(chargeRatio,Sizes_initial,'b.',modifiedChargeRatio,modifiedSize
s,'r.') 
xlabel('Charge ratio');ylabel('Size'); 
[p2,~,stats2]=kruskalwallis(modifiedSizes, 
modifiedChargeRatio,'.'); % p2=0.0708 
compare2=multcompare(stats2); 
  
%% Filtering data and then statistics on them 
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% To something more sensible, the data that were outside of the 
constraints 
% were removed to see if similar results would be obtained. 
Condtions that 
% produced sizes greater than 300nm after being centrifuged were 
removed. 
  
goodData=find(Sizes_firstcentrifuge<315); % To account for 5% error 
in measuring sizes, in case this occured 
goodSizes=Sizes_initial(goodData); % Plotting to compare initial 
sizes 
goodChargeRatios=chargeRatio(goodData); 
figure(7); 
plot(chargeRatio,Sizes_initial,'r.',goodChargeRatios,goodSizes,'b.')
; 
axis([0 1.1 150 315]); xlabel('Charge ratio'); ylabel('Size'); 
  
[p3,~,stats3]=kruskalwallis(goodSizes,goodChargeRatios,'.'); % 
p3=0.0017 
compare3=multcompare(stats3); % It works! 
  
%% Plotting the surface that Dr. Zhong wants 
  
% close all 
for i=0:length(Sizes_firstcentrifuge)/3-1 
    n1=3*i+1; n2=3*i+3; 
    meanSizes_initial(i+1)=mean(Sizes_initial(n1:n2)); 
    meanChargeRatios(i+1)=mean(chargeRatio(n1:n2)); 
    meanCH(i+1)=mean(CH(n1:n2)); 
    meanDS(i+1)=mean(DS(n1:n2)); 
    meanCa(i+1)=mean(Ca(n1:n2));     
end 
m=1;n=1; 
for i=1:length(meanCH) 
    sortedSizes_initial(m,n)=meanSizes_initial(i); 
    sortedChargeRatios(m,n)=meanChargeRatios(i); 
    sortedCH(m,n)=meanCH(i); 
    sortedCa(m,n)=meanCa(i); 
    sortedDS(m,n)=meanDS(i); 
    if mod(m,3)==0 
        m=1; 
        n=n+1; 
    else 
        m=m+1; 
    end 
end 
  
figure();subplot(321),plot(sortedCH,sortedChargeRatios,'--.'); 
xlabel('[CH]');ylabel('Charge ratio'); 
subplot(322),plot(sortedCa,sortedChargeRatios,'--.'); 
xlabel('[Ca]');ylabel('Charge ratio'); 
subplot(323),plot(sortedDS,sortedChargeRatios,'--.'); 
xlabel('[DS]');ylabel('Charge ratio'); 
subplot(324),plot(sortedChargeRatios,sortedSizes_initial,'--.'); 
xlabel('Charge ratio');ylabel('Size'); 
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subplot(325),plot(sortedDS,sortedSizes_initial,'--.'); 
xlabel('[DS]');ylabel('Size'); 
subplot(326),plot(sortedCH,sortedSizes_initial,'--.'); 
xlabel('[CH]');ylabel('Size'); 
  
positiveEffect=sortedCH+sortedCa; 
figure();subplot(211),plot3(sortedChargeRatios,sortedDS,sortedSizes_
initial,'.--'); 
xlabel('Charge ratio');ylabel('[DS]');zlabel('Size'); 
subplot(212);plot3(positiveEffect,sortedDS,sortedSizes_initial,'.--
'); 
xlabel('[CH]+[Ca]');ylabel('[DS]');zlabel('Size'); 
 
A.2. MATLAB function for the computational model 
 
function [Size inputCR]=SizePredictor3(CHVol,DSCH,CaVol,totalVolume) 
% This function was developed in order to linearly interpolate the size 
% based on the parameters that most accurately represent the input 
% paramters. Once the input data are selected, a weighted average is 
taken 
% of the remaining sizes, and then the size is calculated. 
% The inputs for CHVol and CaVol are both in uL, assuming 4 mg/mL and 
10 
% mg/mL stock solutions. the input for totalVolume is in mL. The DSCH 
value 
% is the volumetric ratio of DS:CH, and the input should be a fraction 
% representing this ratio. 
  
global meanCH meanCa meanDS meanSizes_initial meanChargeRatios 
  
load('modeling_data_v2.mat'); 
  
% Converting the input volumes into concentrations 
inputCH=4*CHVol/totalVolume; 
inputCa=10*CaVol/totalVolume; 
inputDS=4*DSCH*CHVol/totalVolume; 
inputCR=(inputCa+inputCH)/inputDS; 
  
original2=searching(meanDS,inputDS); 
altSizes=meanSizes_initial(original2); 
altCH=meanCH(original2); 
altCa=meanCa(original2); 
  
original3=searching(altCH,inputCH); 
altSizes=altSizes(original3); 
altCa=altCa(original3); 
  
original4=searching(altCa,inputCa); 
  
Size=mean(altSizes(original4)); 
  
output=[Size inputCR]; 
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function output=searching(V,value) 
    % This function looks through the input dataset V for the data that 
are 
    % the most similar to 'value' 
     
    uniqueV=unique(V); 
    ind1=find(uniqueV<value); 
    ind2=find(uniqueV>value); 
    ind3=find(uniqueV==value); 
    if isempty(ind3)==0 
        output=find(V==uniqueV(ind3)); 
    else 
        if isempty(ind1)==1 
            ind1=find(min(uniqueV)); 
        elseif isempty(ind2)==1 
            ind2=find(min(uniqueV)); 
        end 
     
        if length(ind1)>1||length(ind2)>1 
            ind1=ind1(end); 
            ind2=ind2(1); 
        end 
        V_ind1=find(V==uniqueV(ind1)); 
        V_ind2=find(V==uniqueV(ind2)); 
        output1=[V_ind1 V_ind2]; 
        score=abs((output1-value)/value); 
        output1=find(score==max(score));score(score==max(score))=0; 
        output2=find(score==max(score)); 
        output=[output1 output2]; 
    end 
end 
  
end 
 
 
A.3. Testing the computational model 
 
%% Testing the model 
clear 
load('modeling_data_v1.mat'); 
load('modeling_data_v2.mat'); 
load('multifactorial_data_v3.mat'); 
  
testCH=250:50:500; 
testCa=0:48:192; 
testDSCH=1:1:6; 
testVol=10:10:40; 
  
j=1;k=1;l=1;m=1;n=1; 
for j=testVol 
    for k=testCa 
        for l=testCH 
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            for m=testDSCH 
                [sizzle chargeRat]=SizePredictor2(l,m,k,j); 
                condition(n,:)=[j k m l sizzle chargeRat]; 
                n=n+1; 
            end 
        end 
    end 
end 
  
resultVol=condition(:,1); 
resultCa=condition(:,2); 
resultDSCH=condition(:,3); 
resultCH=condition(:,4); 
resultSizes=condition(:,5); 
resultChargeRatios=condition(:,6); 
  
%% Plotting the model 
figure(1);plot(resultChargeRatios,resultSizes,'b.',meanChargeRatios,mea
nSizes_initial,'r.'); 
xlabel('Charge ratio'); 
ylabel('NP diameter (nm)'); 
legend('Predicted','Actual','Location','best'); 
  
% Filtering based on size 
goodSizes1=meanSizes_initial(meanSizes_initial<315); 
goodSizes2=resultSizes(resultSizes<315); 
goodCR1=meanChargeRatios(meanSizes_initial<315); 
goodCR2=resultChargeRatios(resultSizes<315); 
  
figure(2);plot(goodCR2,goodSizes2,'b.',goodCR1,goodSizes1,'r.'); 
xlabel('Charge ratio'); 
ylabel('NP diameter (nm)'); 
legend('Predicted','Actual','Location','best'); 
  
%% Error in model 
  
testCH=[250 500]; 
testCa=[0 96 192]; 
testDSCH=[1 3 6]; 
testVol=[10 20 40]; 
  
j=1;k=1;l=1;m=1;n=1; 
for j=testVol 
    for k=testCa 
        for l=testCH 
            for m=testDSCH 
                [sizzle1 chargeRat1]=SizePredictor2(l,m,k,j); 
                condition1(n,:)=[j k m l sizzle1 chargeRat1]; 
                n=n+1; 
            end 
        end 
    end 
end 
  
EresultVol=condition1(:,1); 
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EresultCa=condition1(:,2); 
EresultDSCH=condition1(:,3); 
EresultCH=condition1(:,4); 
EresultSizes=condition1(:,5); 
EresultChargeRatios=condition1(:,6); 
  
error=abs(EresultSizes-meanSizes_initial')./meanSizes_initial'*100; 
figure(3);plot(meanSizes_initial,error,'.'); 
xlabel('Average Size'); ylabel('Error(%)'); 
 
 
A.4. Analysis of Centrifugation data 
 
%% Size dependence on centrifugation 
clear, clc, close all 
  
load('centrifugation_sizeData.mat'); 
% Four matrices are loaded. The first column of each is the size, 
followed 
% by the PDI, and then the count rate. The matrices correspnod to the 
% initial size, the sizes after the first centrifugation, and the size 
% after the secon centrifugation. The last matrix is speed at which 
each 
% solution was centrifuged at (in krpm). THe sizes are in nm, and the 
count 
% rates are in kcps. 
  
%% Sorting Data 
ind=[find(names==1) find(names==2) find(names==3) find(names==4) ... 
    find(names==5) find(names==6) find(names==7) find(names==8)... 
    find(names==9)]; % Sorting based on centrifugation speed (in krpm) 
  
% The for loop sorts the data into columns based on centrifugation 
speed. 
% The outputs include matrices containing the averages of the sizes, 
PDI 
% and count rate in columns based on centrifugation, as well as sorting 
the 
% raw data into columns based on centrifugation speed. The latter are 
9x9 
% matrices with triplicates in each column with each row pertaining to 
a 
% centrifugation speed. 
for j=1:3 
    for i=0:2 
        if i==0 
            loopMat=initial(:,j); 
        elseif i==1 
            loopMat=first_centrifuge(:,j); 
        elseif i==2 
            loopMat=second_centrifuge(:,j); 
        end 
        if j==1 
            meanSizes(i+1,:)=mean(loopMat(ind)); % Average sizes 
70 
 
            Sizes(3*i+1:3*i+3,:)=loopMat(ind);  % Raw data 
        elseif j==2 
            meanPDI(i+1,:)=mean(loopMat(ind)); % Average PDI 
            PDI(3*i+1:3*i+3,:)=loopMat(ind); % Raw data 
        elseif j==3 
            meanCR(i+1,:)=mean(loopMat(ind)); % Average count rates 
            CR(3*i+1:3*i+3,:)=loopMat(ind); % Raw data 
        end 
    end 
end 
figure(1); 
subplot(2,3,[1 2 4 5]),plot(0:2,meanSizes','.--'); 
hold on;plot(0:2,meanSizes(:,6),'o','LineWidth',2,'Color','k'); 
line([0 2],[300 300],'LineWidth',2,'Color','k'); 
line([0 2],[150 150],'LineWidth',2,'Color','k'); 
title('Size'); 
legend('1','2','3','4','5','6','7','8','9','Location','best'); 
ylabel('NP diameter (nm)'); xlabel('Centrifugation events'); 
subplot(2,3,3),plot(0:2,meanCR','--.'); 
hold on;plot(0:2,meanCR(:,6),'o','LineWidth',2,'Color','k'); 
title('Count rate'); 
xlabel('Centrifugation events'); 
ylabel('Count rate (kcps)'); 
subplot(2,3,6),plot(0:2,meanPDI','.--'); 
line([0 2],[0.3 0.3],'LineWidth',2,'Color','k'); 
hold on;plot(0:2,meanPDI(:,6),'o','LineWidth',2,'Color','k'); 
title('PDI'); 
xlabel('Centrifugation events'); 
ylabel('PDI'); 
%% Statistics: One-way ANOVAs 
% One-way ANOVA was performed on these data in order to to determine if 
% there was a significant difference due to centrifugation. First, 
groups 
% were compared based on which step the sizes were measured, and then 
they 
% were compared by centrifugation speed to show that centrifugation 
induced 
% a significant change in size. 
  
for i=0:2 % Signfiicance of centrifugation speed on size 
    statRange1=3*i+1; 
    statRange2=3*i+3; 
    [pA_size(i+1), ~, 
stats_size]=anova1(Sizes(statRange1:statRange2,:)); 
    [pA_PDI(i+1), ~, stats_PDI]=anova1(PDI(statRange1:statRange2,:)); 
    [pA_CR(i+1), ~, stats_CR]=anova1(CR(statRange1:statRange2,:)); 
     
    % If ANOVA returns that the data are significantly different from 
one 
    % another (p<0.05), a multicomparison test was run to determine at 
    % which step resulted in significant change in size. 
    if pA_size(i+1)<0.05 
        'p_size is significant' 
        
figure(100+i);[MC_size,~,H_size(i+1),~]=multcompare(stats_size); 
    else 
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        'p_size is not significantly different' 
    end 
     
    if pA_PDI(i+1)<0.05 
        'p_PDI is significant' 
        figure(200+i);[MC_PDI,~,H_PDI(i+1),~]=multcompare(stats_PDI); 
    else 
        'p_PDI is not significantly different' 
    end 
     
    if pA_CR(i+1)<0.05 
        'p_CR is sginificant' 
        figure(300+i);[MC_CR,~,H_CR(i+1),~]=multcompare(stats_CR); 
    else 
        'p_CR is not significantly different' 
    end 
end 
p1=[pA_size' pA_PDI' pA_CR']; 
     
clear pA_size pA_PDI pA_CR 
  
for i=1:9 % The effects of 
    range1=Sizes(:,i); 
    range2=PDI(:,i); 
    range3=CR(:,i); 
    rangeMatrix1=[range1(1:3)-range1(1:3) range1(4:6)-range1(1:3) 
range1(7:9)-range1(4:6)]; 
    rangeMatrix2=[range2(1:3) range2(4:6) range2(7:9)]; 
    rangeMatrix3=[range3(1:3) range3(4:6) range3(7:9)]; 
    pA_size(i)=anova1(rangeMatrix1); 
    pA_PDI(i)=anova1(rangeMatrix2); 
    pA_CR(i)=anova1(rangeMatrix3); 
     
    % If ANOVA returns that the data are significantly different from 
one 
    % another (p<0.05), a multicomparison test was run to determine at 
    % which speed the data are significantly different. 
    if pA_size(i)<0.05 
        i*1000 
        'p_size is significant' 
        
figure(400+i);[MC_size,~,H1_size(i+1),~]=multcompare(stats_size); 
    else 
        'p_size is not significantly different' 
    end 
     
    if pA_PDI(i)<0.05 
        i*1000 
        'p_PDI is significant' 
        figure(500+i);[MC_PDI,~,H1_PDI(i+1),~]=multcompare(stats_PDI); 
    else 
        'p_PDI is not significantly different' 
    end 
     
    if pA_CR(i)<0.05 
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        i*1000 
        'p_CR is sginificant' 
        figure(600+i);[MC_CR,~,H1_CR(i+1),~]=multcompare(stats_CR); 
    else 
        'p_CR is not significantly different' 
    end 
end 
p2=[pA_size' pA_PDI' pA_CR']; % The p-values comparing the size 
close(2:73) % These are the plots of the data that are not necessary 
for analyzing the statistics 
  
 
A.5. Statistical analysis of time- and dose-responses 
 
%% Time and Dose-dependent statistical analysis 
  
close all, clear, clc 
load('time_dose_responses.mat'); % Loads data for analysis 
  
% Each column is a different parameter. For the dose-dependent 
experiment, 
% the order of the conditions is 0.5x, 1x, 1.5x, PC, and NC. For the 
% time-dependent experiment, the order of the condtions is 24hr, 5hr, 
1hr, 
% PC, and NC. 
  
[p_dose table_dose stats_dose]=anova1(doseRLU); 
p_mc_dose=multcompare(stats_dose); 
  
[p_time table_time stats_time]=anova1(timeRLU); 
p_mc_time=multcompare(stats_time); 
 
A.6. The size data collected from the multifactorial experiment 
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Figure 15: The collected particle sizes that were obtained for the multifactorial 
experiment. From these results it can be seen that the data are not normal, which is why 
nonparametric analysis was required. 
 
  
 
 
 
